文献速递心力衰竭与心肌病

射血分数降低心衰合并慢性肾脏病的循证药物治疗

Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
PubMed 文献 · Circulation · 2022-02-28

该综述探讨射血分数降低心衰(HFrEF)合并慢性肾脏病(CKD)患者的药物治疗。多数药物在CKD 3B期(eGFR最低30 mL/min/1.73 m2)对全因死亡及心血管死亡或心衰住院联合终点安全有效;CKD 4期证据限于SGLT2抑制剂等改善联合终点;CKD 5期证据缺乏。用药后eGFR初期下降常可稳定,不应因此停药。

要点

  • CKD 3B期及以前,多数HFrEF药物对硬终点安全有效。
  • CKD 4期仅SGLT2抑制剂等有联合终点获益证据。
  • CKD 5期(eGFR<15或透析)所有HFrEF药物证据缺乏。

核心结论

  • 多数HFrEF药物在CKD 3B期(eGFR最低30 mL/min/1.73 m2)对全因死亡和心血管死亡或心衰住院联合终点安全有效。
  • CKD 4期有证据支持SGLT2抑制剂及程度较轻的ACEI、vericiguat、地高辛和omecamtiv mecarbil改善心血管死亡/心衰住院。
  • CKD 5期(eGFR<15 mL/min/1.73 m2或透析)对所有HFrEF药物和终点均缺乏安全有效性数据。

研究设计与样本

  • 本文为针对HFrEF合并CKD患者药物治疗的综述。
  • 指出历史关键HFrEF随机临床试验排除了CKD 4和5期(eGFR<30 mL/min/1.73 m2)患者。
  • 近期涉及新药类的HFrEF试验纳入了更严重CKD患者。

主要发现

  • CKD是HFrEF常见合并症,与更严重心衰相关,并为心血管不良结局的强独立危险因素。
  • CKD常影响启动、上调或停用可能救命的HFrEF治疗。
  • 启动ACEI/ARB/MRA/ARNI/SGLT2抑制剂后可见eGFR初期下降,但肾功能常随时间稳定,药物保持临床疗效。

关键数值与推荐

  • CKD 3B期定义为eGFR最低30 mL/min/1.73 m2,多数药物在此范围内安全有效。
  • CKD 4期证据支持SGLT2抑制剂及程度较轻的ACEI、vericiguat、地高辛和omecamtiv mecarbil改善心血管死亡/心衰住院。
  • CKD 5期定义为eGFR<15 mL/min/1.73 m2或透析,所有HFrEF药物证据缺乏。
  • 临床状况稳定或改善时出现eGFR下降不应引起担忧,也不应导致停用救命HFrEF治疗。

临床怎么用

  • 对HFrEF合并CKD 3B期及以前患者,应按指南使用多数循证药物。
  • CKD 4期可考虑SGLT2抑制剂等有联合终点证据的药物。
  • 用药后eGFR初期下降但临床稳定时,不应因此停用救命HFrEF治疗。
  • CKD 5期患者用药需谨慎,因缺乏安全有效性数据。

局限性

  • 历史关键HFrEF随机临床试验排除了CKD 4和5期患者,导致这些人群证据有限。
  • CKD 4期证据主要限于改善心血管死亡/心衰住院联合终点。
  • CKD 5期对所有HFrEF药物和终点均缺乏安全有效性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate (eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF). The presence of CKD is associated with more severe heart failure, and CKD itself is a strong independent risk factor of poor cardiovascular outcome. Furthermore, the presence of CKD often influences the decision to start, uptitrate, or discontinue possible life-saving HFrEF therapies. Because pivotal HFrEF randomized clinical trials have historically excluded patients with stage 4 and 5 CKD (eGFR <30 mL/min/1.73 m2), information on the efficacy and tolerability of HFrEF therapies in these patients is limited. However, more recent HFrEF trials with novel classes of drugs included patients with more severe CKD. In this review on medical therapy in patients with HFrEF and CKD, we show that for both all-cause mortality and the combined end point of cardiovascular death or heart failure hospitalization, most drug classes are safe and effective up to CKD stage 3B (eGFR minimum 30 mL/min/1.73 m2). For more severe CKD (stage 4), there is evidence of safety and efficacy of sodium glucose cotransporter 2 inhibitors, and to a lesser extent, angiotensin-converting enzyme inhibitors, vericiguat, digoxin and omecamtiv mecarbil, although this evidence is restricted to improvement of cardiovascular death/heart failure hospitalization. Data are lacking on the safety and efficacy for any HFrEF therapies in CKD stage 5 (eGFR < 15 mL/min/1.73 m2 or dialysis) for either end point. Last, although an initial decline in eGFR is observed on initiation of several HFrEF drug classes (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/mineralocorticoid receptor antagonists/angiotensin receptor blocker neprilysin inhibitors/sodium glucose cotransporter 2 inhibitors), renal function often stabilizes over time, and the drugs maintain their clinical efficacy. A decline in eGFR in the context of a stable or improving clinical condition should therefore not be cause for concern and should not lead to discontinuation of life-saving HFrEF therapies.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Beldhuis, Lam, Testani, et al. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation. 2022. PMID: 35226558. doi:10.1161/CIRCULATIONAHA.121.052792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。